This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Umeclidinium inhalation


Inhalation powder containing umeclidinium bromide.

Drugs List

  • INCRUSE ELLIPTA 55microgram inhalation powder
  • umeclidinium 55microgram inhalation powder
  • Therapeutic Indications


    Chronic obstructive pulmonary disease



    One inhalation once daily, at the same time of day.

    Maximum daily dose is one inhalation.


    Children under 18 years

    Precautions and Warnings

    Benign prostatic hyperplasia
    Bladder outflow obstruction
    Cardiac arrhythmias
    Glucose-galactose malabsorption syndrome
    Lactose intolerance
    Narrow angle glaucoma
    Severe cardiovascular disorder
    Severe hepatic impairment
    Urinary retention

    Ensure patient has a fast acting bronchodilator available
    Contains lactose
    Check patient is using correct inhaler technique
    Discontinue if paradoxical bronchospasm occurs
    Advise patient not to use for relief of acute attacks
    Advise patient to seek medical advice if treatment is ineffective
    Use regularly to maintain freedom from symptoms

    Pregnancy and Lactation


    Use umeclidinium with caution during pregnancy.

    The manufacturer recommends umeclidinium is not used in pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. At the time of writing there is limited human data available. Risks are unknown.


    Umeclidinium is contraindicated during breastfeeding.

    The manufacturer advises discontinuing breastfeeding or discontinuing umeclidinium. It is unknown whether umeclidinium is excreted in human milk. Effects on exposed infants are unknown.

    Side Effects

    Atrial fibrillation
    Blurred vision
    Bronchospasm (paradoxical)
    Dry mouth
    Hypersensitivity reactions
    Increased intra-ocular pressure
    Ocular pain
    Rhythm idioventricular
    Supraventricular tachycardia
    Upper respiratory tract infection
    Urinary retention
    Urinary tract infections
    Ventricular extrasystoles


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: December 2020

    Reference Sources

    Summary of Product Characteristics: Incruse Ellipta 55 micrograms inhalation powder, pre-dispensed. GlaxoSmithKline (Ireland) Limited. Revised September 2019.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.